The era of multigene panels comes? The clinical utility of Oncotype DX and MammaPrint

Xin, Ling, Liu, Yin Hua, Martin, Tracey Amanda ORCID: https://orcid.org/0000-0003-2690-4908 and Jiang, Wen Guo ORCID: https://orcid.org/0000-0002-3283-1111 2017. The era of multigene panels comes? The clinical utility of Oncotype DX and MammaPrint. World Journal of Oncology 8 (2) , pp. 34-40. 10.14740/wjon1019w

Preview

PDF - Published Version Available under License Creative Commons Attribution Non-commercial. Download (223kB) | Preview

Abstract

The AJCC Cancer Staging Manual, eighth edition published in late 2016, will become the new global guideline for cancer diagnosis and treatment from January 1, 2018. The new edition for the tumor staging system has numerous updates, including building up the prognostic stage group of tumors for the first time and adding a large number of non-anatomical factors into the prognostic evaluation. Oncotype DX and MammaPrint are two of the genomic predictors that will be part of routine clinical practice in the future. Numerous studies have proved the clinical utility of multigene panels in predicting clinical outcome and treatment response. Here we present our review of the studies on these multigene panels and their application to breast cancer.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine
Publisher:	Elmer Press
ISSN:	1920-4531
Funders:	Life Sciences Network of Wales, Cancer Research Wales and the Yiling Foundation Scholarship
Date of First Compliant Deposit:	20 November 2017
Date of Acceptance:	20 November 2017
Last Modified:	04 May 2023 17:35
URI:	https://orca.cardiff.ac.uk/id/eprint/106755

Citation Data

Actions (repository staff only)

Edit Item